Funding
Curetis has increased its first financing by a further €1.5 million, bring the round to €20 million in total.
This additional financing will enable Curetis to complete the development of its first diagnostics through to market entry. At the same time, the company has added internationally recognised expertise in pneumology, intensive care medicine, and microbiology to its new Medical Advisory Board.
The second closing was subscribed to by one of Curetis’ current investors.
Earlier this year, Curetis received ISO 13485 certification for its quality management system, priming the company to launch its first products. “The ISO certification reflects our strong commitment to quality and is an important milestone in the path toward regulatory clearance of our products,” said Andreas Boos, Head of R&D and Managing Director.
At the same time, Curetis announced the inauguration of its new Medical Advisory Board, which will assist with the design of its clinical studies, advise on product development and suggest future clinical applications.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
